Aveanna Healthcare (NASDAQ:AVAH) Issues Quarterly Earnings Results

Aveanna Healthcare (NASDAQ:AVAH) issued its earnings results on Thursday. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.05, FiscalAI reports. Aveanna Healthcare had a return on equity of 481.69% and a net margin of 9.25%.The company had revenue of $647.92 million during the quarter, compared to analysts’ expectations of $613.22 million. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year.

Here are the key takeaways from Aveanna Healthcare’s conference call:

• Aveanna posted strong Q1 results with revenue of about $648 million, up 15.9% year over year, and adjusted EBITDA of $84.4 million, up 25.2%, driven by better rates, higher volumes, and operational efficiencies.
• The company raised full-year 2026 guidance to revenue of $2.56 billion-$2.58 billion and adjusted EBITDA of $328 million-$332 million, excluding the pending Family First acquisition.
• Preferred payer strategy continues to gain traction across all businesses, with 4 new PDS preferred payer agreements, 4 new Home Health agreements, and 2 new Medical Solutions agreements in Q1.
• Management said the new CMS Home Health moratorium should not affect Aveanna or its Family First acquisition, and it does not change the company’s 2026 or 2027 business plans.
• Balance sheet and cash generation remain solid, with liquidity of about $525 million and net leverage at 3.8x, while management reiterated a path toward further deleveraging alongside tuck-in acquisitions.

Aveanna Healthcare Trading Up 9.9%

Shares of Aveanna Healthcare stock opened at $7.44 on Friday. The stock has a market capitalization of $1.62 billion, a PE ratio of 7.29 and a beta of 1.93. The company has a debt-to-equity ratio of 6.62, a current ratio of 1.32 and a quick ratio of 1.32. The company’s fifty day simple moving average is $6.71 and its 200-day simple moving average is $7.92. Aveanna Healthcare has a 1-year low of $3.73 and a 1-year high of $10.32.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: AVAH reported Q1 2026 earnings of $0.18 per share, beating estimates of $0.13, while revenue came in at $647.9 million, above the $613.2 million consensus. Article: Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: The company said revenue rose 15.9% year over year, net income increased to $41.7 million from $5.2 million, and adjusted EBITDA climbed 25.2% to $84.4 million, signaling improving operating momentum. Article: Aveanna Healthcare Shares Climb After Strong Quarterly Results and Higher Guidance
• Positive Sentiment: Management also raised full-year 2026 guidance, boosting revenue outlook to $2.56 billion-$2.58 billion and adjusted EBITDA guidance to $328 million-$332 million, which likely supports investor confidence in the rest of the year. Article: Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance
• Neutral Sentiment: Additional coverage from earnings-call summaries and transcripts highlighted the same beat-and-raise results, reinforcing the market’s positive reaction rather than adding new drivers. Article: Aveanna Healthcare Holdings Inc (AVAH) Q1 2026 Earnings Call Highlights

Analysts Set New Price Targets

AVAH has been the topic of a number of recent analyst reports. BMO Capital Markets cut their price target on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. Barclays dropped their target price on shares of Aveanna Healthcare from $11.00 to $9.50 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. Weiss Ratings downgraded Aveanna Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Zacks Research lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, UBS Group boosted their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.33.

Insider Buying and Selling

In related news, CEO Jeff Shaner sold 173,225 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $1,248,952.25. Following the completion of the transaction, the chief executive officer directly owned 2,650,892 shares in the company, valued at approximately $19,112,931.32. The trade was a 6.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Edwin C. Reisz sold 60,769 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $438,144.49. Following the completion of the transaction, the insider owned 1,447,057 shares of the company’s stock, valued at approximately $10,433,280.97. The trade was a 4.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 738,957 shares of company stock valued at $5,458,175 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Aveanna Healthcare

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its stake in Aveanna Healthcare by 1,001.5% in the 4th quarter. Invesco Ltd. now owns 360,464 shares of the company’s stock worth $2,945,000 after purchasing an additional 327,738 shares in the last quarter. Mackenzie Financial Corp grew its position in shares of Aveanna Healthcare by 12.7% during the fourth quarter. Mackenzie Financial Corp now owns 216,200 shares of the company’s stock valued at $1,810,000 after purchasing an additional 24,447 shares in the last quarter. Zimmer Partners LP purchased a new position in shares of Aveanna Healthcare during the fourth quarter valued at about $6,189,000. Voloridge Investment Management LLC bought a new stake in shares of Aveanna Healthcare in the fourth quarter worth about $1,915,000. Finally, Millennium Management LLC lifted its position in shares of Aveanna Healthcare by 1,007.1% in the fourth quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock worth $9,107,000 after buying an additional 1,014,030 shares in the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.